Related Experiment Videos
Current concepts on active immunization against respiratory syncytial virus for infants and young children
Martin C J Kneyber1, Jan L L Kimpen
1Wilhelmina Children's Hospital/University Medical Center, Utrecht, The Netherlands.
Insights
Developing an effective respiratory syncytial virus (RSV) vaccine remains challenging due to historical issues and incomplete understanding of immune responses. Current research explores various candidate vaccines, but widespread immunization is likely 5-10 years away.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a primary cause of severe respiratory infections in infants and young children.
- Past vaccine development efforts faced significant setbacks, including adverse events in the 1960s.
- Limited understanding of RSV-induced immune responses has hindered progress.
Purpose of the Study:
- To review the development of candidate vaccines against RSV.
- To discuss the challenges and future prospects for RSV vaccine availability.
Main Methods:
- Review of intensive research over the past two decades on RSV vaccine candidates.
- Analysis of various vaccine types, including subunit vaccines and temperature-sensitive mutants.
- Consideration of human testing data for selected candidates.
Main Results:
- Several promising RSV vaccine candidates have emerged, with some undergoing human trials.
- Candidate vaccines include subunit formulations (PFP-1, PFP-2, BBG2Na) and cold-passaged/temperature-sensitive mutants.
- Passive immunization is available, but an effective vaccine is still under development.
Conclusions:
- Despite progress, significant challenges and uncertainties persist in developing a safe and effective RSV vaccine.
- Routine immunization against RSV is not expected for at least another 5 to 10 years.
Abstract:
Respiratory syncytial virus (RSV) is the most important causative agent of viral respiratory tract infections in infants and young children. Passive immunization against RSV became available recently, but this does not apply to an effective vaccine as a result of dramatic adverse results of immunization with a RSV candidate vaccine in the 1960s and the lack of full knowledge of the immune response induced by RSV. Nonetheless intensive research during the past two decades has resulted in several interesting candidate vaccines, of which some have gone through testing in humans. These include the subunit vaccines PFP-1, PFP-2, BBG2Na and cold-passaged/temperature-sensitive mutants. The development of candidate vaccines against RSV is discussed. Because of questions, uncertainties and difficulties with the development of effective vaccines against RSV, it will probably be at least another 5 to 10 years before routine immunization against RSV becomes available.